Member Info for Ctw2014

I notice (belatedly) that Peel Hunt initiated coverage on this share on 25th October with a buy investment rating and a target price of 150p.

It’s been pretty clear for a while that it has not been working out with Xcleris so this clears the decks for a new arrangement. Pretty big hint in David Budd’s comments that this could be with Sysmex. Time will tell.

Yes, the Interims confirmed that they have stockpiled a large number of blocks to enable them to fulfil orders for processed marble despite the Winter shutdown in the quarries. Looking like things are falling into place now.

According to the website we need a commitment to an appraisal well to extend the licence beyond the end of 2017.

Hep C kit being launched at the IFCC World Lab 2017 Congress in Durban South Africa now.

Well, this might be a bit risky and require some patience but it’s nice to see the Pru upping its stake to over 10%.

Great to see the distribution deal done just in time for the results and presentation tomorrow. No reaction from the market yet because, in my view, this is still way off the radar. Hopefully they will drum up some publicity and interest at tomorrow’s presentation.

...remember. Bound to say something about distribution and commercial plans generally.

Another stonking great trade gone through at the published mid price. My bet is that it’s buy which has been worked for some time. Bearing in mind the recent holdings RNS the clues are there.

.... on Genedrive’s twitter account showing the first Genedrive HCV ID kit ready for shipment.

With the results out next Tuesday and a presentation to give, they will be keen to say something about distribution plans, so between now and then, or on the day, I would guess.

You’re welcome Troy. No information on an announcement but they did send me a copy of their ‘promotional brochure’ for the HCV test so it looks like they are gearing up and I would guess we will hear something soon.

I found the following email from Genedrive reassuring: ‘You are correct that there are several rapid antibody tests available for HCV currently, including the OraSure HCV test. However, these tests are only viable for screening as have variable performance, in particular with patients with coinfections such as HIV. WHO guidelines advise that treatment decisions can only be based on the results of a molecular test either qualitative or quantitative meaning a positive test from a test such as these requires confirmation from molecular testing. All current molecular tests on the market require large, expensive equipment and are therefore only performed on centralised laboratories. These tests are also very cost prohibitive as require a large upfront instrument cost and continual running costs. Genedrive HCV ID kit is a qualitative molecular assay, that does not require centralised instrumentation. It is single throughout and can be used by decentralised laboratories or clinics. It doesn’t require any large upfront cost or ongoing maintenance costs making it an affordable option for decentralised testing.’

Good price to top up at. Let’s hope we get news on a nice juicy order or two now to give this a boost.

It was nice while it lasted. Volume down and back out with a small profit. Will watch for now.

I see Genedrive are at this event tomorrow. Wonder if we will get an RNS on the distribution deal? Hopefully an interview too. Let's see.

Good to see someone build a notifisble interest. 6,354,660 shares is a decent chunk. Unless my google research has got the wrong Andrew Hugh John Muir (there can't be many!) he appears to be a retired company director, and former stockbroker with J P Morgan Casenove. Hmmmm, I reckon he might know a thing or two about investing, don't you? Pl DYOR.

Easy to sell but can't get a live quote to buy even £1000 worth. Good sign.

Whoops!

One positive thing about a share that has been falling for a while is that (sadly) most holders will be underwater by a significant margin. It follows that they are less likely to sell on a rise, at least until they are break even or in profit. Accordingly, we will not necessarily see a fallback after this rise (although nobody really knows). So far though, this is looking very strong. Whatever you think of the Mail it has a huge readership. This is also now high on the LSE Risers board which, in itself, generates interest/buys. GLA